Safety and Immunogenicity of the Measles Vector-Based SARS-CoV-2 Vaccine Candidate, V591, in Adults: Results from a Phase 1/2 Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Trial
EBioMedicine(2022)
Key words
COVID-19,SARS-CoV-2,Vaccine
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined